European Journal of Cancer and Clinical Oncology最新文献

{"title":"Low-power laserthermia for the treatment of small hepatocellular carcinoma","authors":"Guan-Tarn Huang ,&nbsp;Teh-Hong Wang ,&nbsp;Jin-Chuan Sheu ,&nbsp;Norio Daikuzono ,&nbsp;Juei-Low Sung ,&nbsp;Mu-Zong Wu ,&nbsp;Ding-Shinn Chen","doi":"10.1016/0277-5379(91)90429-H","DOIUrl":"10.1016/0277-5379(91)90429-H","url":null,"abstract":"<div><p>Laserthermia by a novel interstitial probe adapted to low power Nd-YAG laser machine was used to treat small hepatocellular carcinoma (HCC). The set condition was 43–45°C in thermocouple with power of 2–3 W and the duration 20–30 min. In the 5 cases studied, 1 had a good result with total necrosis of the tumour without recurrence in 16 months. 1 died of liver failure 2.5 months later although death was not related to the procedure. 1 patient died of progressive disease 18 months later. The remaining 2 had recurrent tumours 5 and 12 months later, although the treated small tumours showed good response. Histological examination showed cell degeneration and necrosis. It is concluded that laserthermia is potentially useful in the treatment of the patients with small HCC.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1622-1627"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90429-H","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder","authors":"A. Boutan-Laroze ,&nbsp;M. Mahjoubi ,&nbsp;J.P. Droz ,&nbsp;P. Charrot ,&nbsp;P. Fargeot ,&nbsp;P. Kerbrat ,&nbsp;A. Caty ,&nbsp;P.M. Voisin ,&nbsp;M. Spielmann ,&nbsp;A. Rey ,&nbsp;B. Giraud","doi":"10.1016/0277-5379(91)90447-L","DOIUrl":"10.1016/0277-5379(91)90447-L","url":null,"abstract":"<div><p>70 patients with advanced transitional cell carcinoma of the bladder received methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). Complete responses (CR) were obtained in 13 of the 67 (19%) evaluable patients and partial responses (PR) in 25 patients for an objective response rate of 57% (95% CI 45–69%). Of the 54 patients who have had a minimum follow-up of 2 years, 8 patients (15%) are disease-free or have stable residual disease. Median survival of the 70 patients was 13 months. Toxicity was acceptable with no drug-related deaths. Because of myelosuppression, only 15 patients (21%) received treatment without delays in drug administration or modifications from the planned schedule. Our results confirm that this regimen is effective, with some patients being long-term survivors.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1690-1694"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90447-L","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I study of DABIS maleate given once every 3 weeks","authors":"Maria E.L. van der Burg ,&nbsp;AndréS.Th. Planting ,&nbsp;Gerrit Stoter ,&nbsp;Cathy McDaniel ,&nbsp;Charles J. Vecht ,&nbsp;Jaap Verweij","doi":"10.1016/0277-5379(91)90433-E","DOIUrl":"10.1016/0277-5379(91)90433-E","url":null,"abstract":"<div><p>DABIS maleate is an alkylating quaternary nitrogen. In a phase I study DABIS maleate was administered as a single intravenous infusion once every 3 weeks. 32 patients with solid tumours were studied, at least 3 per dose level (50–1400 mg/m²). Dose-limiting toxicity was severe paresthaesias in the face, around the mouth and in the tongue. Cerebellar ataxia developed at 750 mg/m² or higher. Haematological toxicity was minimal. Nausea and vomiting were mild to moderate. No other non-haematological side-effects were noted. The recommended dose for phase II studies at once every 3 weeks is 750 mg/m² intravenously as a 15 min infusion.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1635-1637"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90433-E","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12945231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis of reported correlations between prognostic factors in breast cancer: Does axillary lymph node metastasis represent biology or chronology?","authors":"Indraneel Mittra ,&nbsp;Kenneth D. MacRae","doi":"10.1016/0277-5379(91)90418-D","DOIUrl":"10.1016/0277-5379(91)90418-D","url":null,"abstract":"<div><p>A statistical overview of published results on correlations between various prognostic factors in breast cancer was undertaken. A distinction was made between clinical (or anatomical) prognostic factors—namely, axillary lymph node status and tumour size—and eight different biological prognostic factors. The latter included: tumour grade, oestrogen and progesterone receptor status, thymidine labelling index, DNA ploidy, S-phase fraction, epidermal growth factor receptor expression and c-<em>erb</em>B-2 gene amplification (or overexpression). 139 articles were eligible for review which reported a total of 432 individual correlations. A simple form of meta-analysis was employed: the counting method, in which the number of studies achieving a statistically significant correlation or not were counted. For each possible correlation examined, the proportion of studies showing a statistically significant correlation was calculated and an exact binomial 99% confidence interval determined for that proportion. If the 99% confidence interval included 5% (the proportion of correlations that would be expected to be statistically significant if the null hypothesis was true), it was taken as failing to exclude the null hypothesis of a zero correlation, while if it excluded 5% it was taken as rejecting the null hypothesis of a zero correlation. A broad agreement was found among published reports on the existence of a statistically significant correlation between the various biological prognostic factors in breast cancer. Of the 20 correlation examined, 18 had a 99% confidence interval excluding 5%, thus rejecting the null hypothesis of a zero correlation. On the other hand, a completely different result was obtained when reports on possible correlations between lymph node status and tumour size on the one hand and the eight biological prognostic factors on the other were analysed. Of the 16 correlations examined, 13 had a 99% confidence interval including 5%, failing to reject the null hypothesis of a zero correlation. These observations suggest the hypothesis that the prognostic influence of node status and tumour size cannot be explained by an analysis of the biology of breast cancer; and is compatible with the contention that axillary node status is merely a reflection of the relative chronological age of breast cancer.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1574-1583"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90418-D","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12998574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppression by sorted CD8+CD11b− cells from T-cell growth factor-activated peripheral blood lymphocytes on cytolytic activity against tumour in patients with gastric carcinoma","authors":"T. Ebihara,&nbsp;N. Sakai,&nbsp;S. Koyama","doi":"10.1016/0277-5379(91)90439-K","DOIUrl":"10.1016/0277-5379(91)90439-K","url":null,"abstract":"<div><p>To confirm the phenotypic characteristics of lymphokine-activated suppressor (LAS)effector cells, we isolated CD8⁺CD11b⁻ and CD8⁻CD11b⁻ cells from T-cell growth factor (TCGF)-activated peripheral blood lymphocytes (PBL) in 7 patients with gastric carcinoma (4 non-resectable and 3 resectable carcinoma) and 3 healthy controls. Sorted CD8⁺CD11b⁻ cells from 3 of the patients with non-resectable carcinoma and from 1 of the patients with resectable carcinoma showed LAS cell activity. However, the LAS cell activity could not be observed in CD8⁺CD11b⁻ cells from healthy controls. In addition, a sorted CD8⁻CD11b⁻ subset of cells from both cancer patients and control did not express any suppressive activity. These facts clearly show that the cell populations responsible for suppression of cell-mediated antitumour immunity reside within CD8⁺CD11b⁻ T-cells, at least in patients with advanced carcinoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1654-1657"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90439-K","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12998576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador)","authors":"Eva Kovacs ,&nbsp;Tibor Hajto ,&nbsp;Katerina Hostanska","doi":"10.1016/0277-5379(91)90443-H","DOIUrl":"10.1016/0277-5379(91)90443-H","url":null,"abstract":"<div><p>We investigated alteration in DNA repair during therapy with an immunomodulator. 14 patients with advanced breast cancer were treated parenterally with Iscador, an extract of <em>Viscum album</em> (mistletoe). As a parameter for measurement of DNA repair the incorporation of (³H) thymidine into DNA of unstimulated lymphocytes after ultra violet light (UV) damage was taken. The DNA repair values in the patients were very low before treatment and on day 1: on average 16% of those in a healthy control population. Values started to increase on day 2 and on days 7–9 were on average 2.7 times higher than before treatment. <span><math><mtext>12</mtext><mtext>14</mtext></math></span> patients showed an improvement in repair. The values of spontaneous DNA synthesis were not altered during the treatment. We suggest that the increase of DNA repair could be due to a stimulation of repair enzymes by lymphokines or cytokines secreted by activated leukocytes or an alteration in the susceptibility to exogenic agents resulting in less damage.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1672-1676"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90443-H","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unproven methods in oncology","authors":"Simon P. Hauser","doi":"10.1016/0277-5379(91)90412-7","DOIUrl":"10.1016/0277-5379(91)90412-7","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1549-1551"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90412-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytogenetic and breakpoint cluster region (bcr) changes in chronic myelogenous leukaemia treated with low-dose alpha interferon","authors":"Robin Aitchison ,&nbsp;Ellen McSweeney ,&nbsp;Les Butler ,&nbsp;Leanne Weidemann ,&nbsp;Adrian C. Newland","doi":"10.1016/0277-5379(91)90562-R","DOIUrl":"10.1016/0277-5379(91)90562-R","url":null,"abstract":"<div><p>THERE is continuing interest in the role of alpha interferon in the treatment of chronic myelogenous leukaemia (CML), both because it is an effective agent for disease control and because cytogenetic improvement is seen in a significant proportion of cases. We have entered 23 patients with chronic phase CML into a study using standard oral chemotherapy in conjunction with interferon alfa-2b (IFN) 3 million units (MU) subcutaneously three times a week. All patients were 100% Ph¹-positive and <span><math><mtext>22</mtext><mtext>23</mtext></math></span> had a detectable bcr rearrangement at the start of IFN therapy. The median duration of chronic phase before IFN treatment was 18 months (range 1–56 months). Oral chemotherapy was given with IFN in <span><math><mtext>22</mtext><mtext>23</mtext></math></span> patients to try to achieve complete haematological remission. Treatment was well tolerated; IFN dosage reduction was necessary in seven patients: three with myelosuppression, one with immune thrombocytopenia and three with abnormal liver function tests. The mean duration of IFN treatment is 17 months (range 6–38 months). There has been a reduction in the proportion of Ph¹-positive metaphases in six (26%) of the 23 patients (mean of six = 56% Ph¹-positive, range 7–97%). The bcr remained rearranged in all those showing a cytogenetic response. Median duration of follow up is now 31 months since the start of interferon treatment (range 21–79 months) and 43 months since diagnosis (range 29–82 months). Four patients have gone into blast transformation (three myeloid and one lymphoid) and four have died, three following blast transformation and one with myelofibrosis and marrow failure. These results suggest that treatment with comparatively low-dose IFN (9 MU/week) is well tolerated and produces karyotypic improvement in a significant proportion of cases. Longer follow-up will be required to assess the group's survival and the relationship of patient survival to cytogenetic response.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Page S27"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90562-R","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76479994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth factor requirements of human colorectal tumour cells: Relations to cellular differentiation","authors":"Lily Huschtscha ,&nbsp;Enrique Rozengurt,&nbsp;Walter F. Bodmer","doi":"10.1016/0277-5379(91)90445-J","DOIUrl":"10.1016/0277-5379(91)90445-J","url":null,"abstract":"<div><p>Human colorectal tumour lines that exhibit different degrees of differentiation were studied to define their growth requirements. The poorly differentiated cell lines SW620, SW480, SW48 and SW837 proliferated in Dulbecco's modified Eagle's medium without exogenously added growth factors. In contrast, the moderately differentiated cell lines SW1222, HT29, PC/JW and LS174T proliferated only in medium supplemented with growth factor. SW1222 and HT29 cells required transferrin for growth, which was improved by other growth-promoting factors including epidermal growth factor (SW1222) and sodium selenite (HT29). PC/JW and LS174T required both insulin and transferrin for optimal growth. The tumour cell lines could be passaged continuously in serum-free medium supplemented with growth factor and in some cases they grew better than in serum-supplemented medium. The serum-free growth conditions should prove useful for studies on differentiation in colorectal cell lines and their interactions with growth factors.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1680-1684"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90445-J","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early cardiac toxicity of 4′-iodo-4′-deoxydoxorubicin","authors":"Fabrizio Villani,&nbsp;Milena Galimberti,&nbsp;Roberto Comazzi","doi":"10.1016/0277-5379(91)90423-B","DOIUrl":"10.1016/0277-5379(91)90423-B","url":null,"abstract":"<div><p>4′-iodo-4′-deoxydoxorubicin was administered intravenously to 35 patients with advanced malignant neoplasms. The doses were escalated as follows: 2, 4, 6, 7, 10, 14, 19, 26, 52, 70, 80 and 90 mg/m². Myocardial function was assessed by Holter monitoring and echocardiography. The prevalence of arrhythmias that could be attributed to the drug in the 24 h following infusion was 14.3% (supraventricular) and 10.6% (ventricular). Echocardiographic heart function variables were unchanged at 24 h and 21 days from drug injection. The data indicate the absence of significant, acute cardiotoxic effects of 4′-iodo-4′-deoxydoxorubicin.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1601-1604"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90423-B","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}